This inventor holds 2 USPTO granted patents. Top assignee: Novo Nordisk A/s. Active years: 2007-2015.
Company Filing History:
Years Active: 2007-2015
Title: Lars Hojlund Christensen: Innovator in Insulin Production
Introduction
Lars Hojlund Christensen is a notable inventor based in Vaerlose, Denmark. He has made significant contributions to the field of biotechnology, particularly in the production of insulin analogs. With a total of 2 patents, his work has had a substantial impact on diabetes treatment.
Latest Patents
Christensen's latest patents include a method for making mature insulin polypeptides. This invention relates to a method for producing human insulin analogs by culturing a fungi cell that contains a DNA vector encoding a precursor for human insulin analog. The precursor includes a connecting peptide flanked by cleavage sites at both junctions with the A- and B-chain of the insulin peptide. These cleavage sites are cleaved within the fungi cell, allowing it to secrete a high amount of correctly processed, mature two-chain human insulin analog into the culture media. Another significant patent involves a purification process that utilizes microfiltration at elevated temperatures, enhancing the efficiency of insulin production.
Career Highlights
Lars Hojlund Christensen is associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care. His work at Novo Nordisk has positioned him as a key player in the advancement of insulin production technologies.
Collaborations
Christensen has collaborated with notable colleagues such as Asser Sloth Andersen and Torben K Nielsen. Their combined expertise has contributed to the innovative developments in insulin production.
Conclusion
Lars Hojlund Christensen's contributions to the field of biotechnology, particularly in insulin production, highlight his role as an influential inventor. His patents reflect a commitment to improving diabetes treatment through innovative methods.